Mutated Ras peptides as vaccines in immunotherapy of cancer (Q40846439)

24 September 2017

1 reference

title

Mutated Ras peptides as vaccines in immunotherapy of cancer (English)

1 reference

24 September 2017

1 reference

2

Gaudernack G

1 reference

24 September 2017

Gjertsen MK

1

1 reference

24 September 2017

1 January 1998

1 reference

24 September 2017

1 reference

24 September 2017

74 Suppl 2

1 reference

24 September 2017

489-495

1 reference

T-cell immunity to the joining region of p210BCR-ABL protein

24 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Immunity to Oncogenic Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Ki-ras point mutations and proliferation activity in biliary tract carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

CD28-B7 interactions in T-cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

The dendritic cell system and its role in immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Binding of ras oncogene peptides to purified HLA-DQ(alpha 1*0102,beta 1*0602) and -DR(alpha,beta 1*0101) molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Sequence analysis of peptides bound to MHC class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Identical peptides recognized by MHC class I- and II-restricted T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Interleukin 12: a key modulator of immune function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Peptide‐specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K‐ras p21

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Detection of ras gene mutations in perioperative peripheral blood with pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1423-0410.1998.TB05462.X

10.1111/J.1423-0410.1998.TB05462.X

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9704487